Clinical trials · Missouri
Down Syndrome clinical trials in Missouri
We’re tracking 83 recruiting down syndrome studies with a site in Missouri — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Missouri
- NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
St Louis, MissouriAges Any age - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
City of Saint Peters, MissouriAges 18 years+ - NCT03949855RecruitingPhase 2
Belimumab plus rituximab for primary membranous nephropathy
This study tests whether adding belimumab to rituximab helps people with primary membranous nephropathy (a kidney disease) that has the right blood test marker and specific protein levels. The goal is to improve kidney outcomes and reduce disease activity while keeping treatment safe.
St Louis, MissouriAges 18–75 - NCT04270045Recruiting
Breathing test in babies with bronchopulmonary dysplasia
This trial studies a breathing measurement test (forced oscillometry) in babies who were born early and have bronchopulmonary dysplasia (BPD), a long-term lung condition. It may help doctors better understand how babies’ lungs are working and guide future care.
Kansas City, MissouriAges Any age - NCT04336644Recruiting
Checks heart rhythm continuously or intermittently during treatment
This study compares two ways of monitoring your heart rhythm while you start certain cancer treatments. It may help doctors detect heart rhythm changes earlier and decide which monitoring approach is better.
St Louis, MissouriAges 18 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
St Louis, MissouriAges 1–30 - NCT04742634RecruitingPhase 1/Phase 2
Preemptive drug DEC-C after transplant to reduce hidden cancer
This trial tests whether giving DEC-C (a decitabine-based treatment) soon after an allogeneic transplant can improve outcomes for MDS patients who still have “measurable residual disease” (hidden leftover disease) detectable by a genetic test. It also compares this approach to standard observation if the hidden disease is not detected or if the higher-risk safety checks are not met.
St Louis, MissouriAges 18–75 - NCT04986657Recruiting
Whole genome testing to help diagnose AML or MDS
This study checks whether adding whole genome sequencing (reading a person’s DNA more broadly) alongside standard genetic tests improves the diagnosis process for AML or MDS. It may help doctors decide on the best next steps when AML/MDS is suspected.
St Louis, MissouriAges 18 years+ - NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Kansas City, MissouriAges 1–17 - NCT05219110Recruiting
More fluids for children sick with toxin E. coli
This study looks at whether giving extra (hyper) fluids early helps children with a high-risk E. coli stomach infection. The goal is to improve outcomes by supporting the kidneys during the illness.
St Louis, MissouriAges 9 months–21 years - NCT05219617RecruitingPhase 3
Carisbamate for frequent drop seizures in Lennox-Gastaut
This Phase 3 study tests whether carisbamate can reduce drop seizures in people with Lennox-Gastaut syndrome (LGS). It also checks whether the treatment is safe when added to existing seizure medicines.
Columbia, MissouriAges 4–55 - NCT05388006RecruitingPhase 2
Testing three medicines for Richter transformation in CLL/SLL
This Phase 2 trial studies acalabrutinib, venetoclax, and durvalumab together for Richter transformation (a more aggressive lymphoma) that developed from CLL or SLL. The goal is to improve how well treatment works and how long people can respond.
St Louis, MissouriAges 18 years+ - NCT05434598Recruiting
Whole-genome testing added to standard testing for MDS
This study checks whether adding whole-genome sequencing (a deeper look at DNA) alongside standard genomic tests helps in evaluating myelodysplastic syndrome (MDS). It aims to see if this extra testing is useful and acceptable during routine care—especially for people newly being worked up for MDS.
St Louis, MissouriAges 18 years+ - NCT05462106RecruitingPhase 1/Phase 2
ACI-24.060 study for early Alzheimer’s in adults and Down syndrome
This Phase 1/2 study tests an Alzheimer’s treatment called ACI-24.060 to see if it affects the disease in people with early Alzheimer’s changes. It includes two groups: older adults with early symptoms and people with Down syndrome who also show Alzheimer’s-related changes on brain scans.
St Louis, MissouriAges 35–85 - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
Kansas City, MissouriAges 1 month–21 years - NCT05918861RecruitingPhase 3
Tested heart-risk drug for people with recent heart-attack genetics
This trial studies whether dalcetrapib can lower future heart and blood-vessel risk in people who recently had an ACS (acute coronary syndrome, often a heart attack or unstable chest pain) and have a specific genetic marker. It may help people like you by targeting a risk pathway related to that genetic background.
Springfield, MissouriAges 45 years+ - NCT05975671Recruiting
Survey in pediatric ICU to reduce upfront vancomycin use
This study is a survey and quality-improvement effort in participating children’s intensive care units. It aims to understand and change how doctors decide to start vancomycin (an antibiotic) when sepsis is suspected, to improve care and avoid unnecessary use.
St Louis, MissouriAges Any age - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
St Louis, MissouriAges Any age - NCT06008808RecruitingPhase 1
Ruxolitinib and abatacept to prevent GVHD after haplo transplant
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
St Louis, MissouriAges 18 years+ - NCT06132477RecruitingPhase 4
Study of GLP-1 medicines after weight loss surgery
This study looks at what happens when people taking a GLP-1 medication (like Ozempic) either stop or continue it after weight loss surgery. The goal is to learn whether staying on the medicine helps with long-term weight control.
Columbia, MissouriAges 18 years+ - NCT06193928Recruiting
Long-term safety study of Livmarli in ALGS or PFIC
This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.
Kansas City, MissouriAges Any age - NCT06112418Recruiting
Personalized vs standard care to prevent heart attacks
This trial compares two ways to prevent heart attacks and strokes: one uses a special heart CT scan to guide care, the other uses standard risk factors like blood pressure and cholesterol. You may be eligible if you are older (men over 55, women over 65) and have diabetes, prediabetes, or metabolic syndrome.
St Louis, MissouriAges 55 years+ - NCT06399952Recruiting
Natural history study for Baker Gordon syndrome
This study follows people with Baker Gordon syndrome over time to better understand the condition. Participants and their caregivers share medical records and complete tests and questionnaires.
Columbia, MissouriAges birth–99 years - NCT06428019RecruitingPhase 3
Comparing drug combinations for untreated CLL or SLL
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
Kansas City, MissouriAges 18 years+
Down Syndrome trials by city in Missouri
Where these studies are running in Missouri
Institutions with a site for the recruiting down syndrome studies listed above.
- Washington University in St. Louis · 13 studies
- Children's Mercy Kansas City · 5 studies
- Ellis Fischel Cancer Center / MU Health - University Hospital · 3 studies
- Massive Bio SYNERGY-AI site
- Mercy Hospital Saint Louis
- Research Site
- Saint Luke's Hospital of Kansas City
- Siteman Cancer Center
What taking part in a down syndrome study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Down Syndrome trials in other states
Common questions
- Are there down syndrome clinical trials in Missouri?
- Yes. We're currently tracking 83 recruiting down syndrome studies with a site in Missouri, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a down syndrome study in Missouri?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Missouri to take part?
- Not necessarily. These studies have a site in Missouri, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a down syndrome trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New down syndrome studies open in Missouri regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.